CelLBxHealth plc
CLBX · AIM · Health Care · mcap £6.8m · 0.6p 3 open situations →
- EV
- £4.0m
- EV / EBIT
- –
- Net cash
- £2.9m
- FCF yield
- -143.2%
- Revenue
- £1.2m
- Cash returned
- 0.5%
- Share price 1y
- −72%
- Insiders 12m
- no deals
- Next report
- around 21 Jun
Open · 3
Restructuring and turnaround
Includes Equity fundraise – Cash £2.9m; runway into Q2 2027, closed 15 Jul 2026
Restructure began with the November 2025 raise at 1.0p. CEO Peter Collins left on 6 July 2026 and Jan Groen is Executive Chairman during a CEO search. On 15 July FY2026 guidance of at least £2.1m was maintained. On 21 October guidance was cut to about £1.8m, cash was £1.4m at 30 September, runway shortened to Q1 2027, and FY2027 revenue of £3.0-4.0m was guided.
- Trading view
- Board expects no impact on trading during the transition 6 Jul 2026 ↗
- H1 2026 revenue
- £0.6 million; Q2 £0.4 million, up 100% on Q1 (£0.2 million) 15 Jul 2026 ↗
- Board view
- Confident in continuity of strategy and execution during the transition 15 Jul 2026 ↗
- FY2026 guidance
- About £1.8m, down from at least £2.1m; +29% on FY2025 (£1.4m); 21 Oct 2026 21 Oct 2026 ↗
- FY2027 guidance
- Revenue of £3.0m-£4.0m anticipated 21 Oct 2026 ↗
- Cash
- £1.4m at 30 Sept 2026; £0.8m R&D tax credit expected in coming months 21 Oct 2026 ↗
Next: CEO appointment; Q4 spend and FY2026 results
- 21 Oct 2026 Guidance cut; cash runway shortened; CEO search continues
- 15 Jul 2026 Costs cut; CEO search under way
- 6 Jul 2026 CEO exit; search for successor begins
- 22 Jun 2026 Audited FY2025 results; target and cost cuts confirmed
Cash runway and funding
On 21 October 2026 the company reported cash of £1.4m at 30 September, a monthly burn of £0.4m rising by £0.1m in Q4, and a runway through to Q1 2027 after an expected £0.8m R&D tax credit. This is shorter than the earlier guide of into Q2 2027. The CEO search is also tied to future funding.
- Cash
- £1.4m at 30 September 2026 21 Oct 2026 ↗
- Tax credit
- £0.8m R&D tax credit expected in the coming months 21 Oct 2026 ↗
- Burn
- £0.4m a month in Q3; £0.1m a month more in Q4 21 Oct 2026 ↗
- Runway
- Through to Q1 2027 21 Oct 2026 ↗
Next: R&D tax credit receipt; funding before Q1 2027 runway ends
- 21 Oct 2026 Cash £1.4m; runway to Q1 2027
Conifer Management, L.L.C. towards control
Conifer Management, L.L.C. raised its stake in CelLBxHealth plc from 0% to 29.9% on 23 Dec 2025, crossing 29.9%.
Next: over 30% a holder normally has to make an offer (Rule 9)
- 23 Dec 2025 29.9%
Closed · 3
Company filings. Not investment advice.